Voyager Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Voyager Therapeutics, Inc. (VYGR) had Debt Securities, Available-for-sale, Amortized Cost of $36.47 million as of 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2021-05-10
- 2021-03-31: Debt Securities, Available-for-sale, Amortized Cost $36.47M.
- 2020-12-31: Debt Securities, Available-for-sale, Amortized Cost $71.57M.
- 2020-09-30: Debt Securities, Available-for-sale, Amortized Cost $53.72M.
- 2020-06-30: Debt Securities, Available-for-sale, Amortized Cost $86.30M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2021-03-31 | $36.47M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $71.57M 10-Q · filed 2021-05-10 |
| 2020-09-30 | $53.72M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $86.30M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $86.37M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $196.69M 10-K · filed 2021-02-25 |
| 2019-09-30 | $225.87M 10-Q · filed 2019-11-06 |
| 2018-12-31 | $110.17M 10-K · filed 2020-03-03 |
| 2017-12-31 | $138.78M 10-K · filed 2018-03-14 |
| 2017-09-30 | $77.40M 10-Q · filed 2017-11-02 |
| 2016-12-31 | $137.84M 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |